



Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference

February 8, 2024

MARLBOROUGH, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on March 4th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to [register online](#). It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Akoya website at <https://investors.akoyabio.com/>.

Akoya will also be participating in the upcoming BTIG at Snowbird: MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking place on February 13-14, 2024.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, Phenolmager™ Fusion and Phenolmager HT. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:

Priyam Shah
investors@akoyabio.com

Media Contact:

Christine Quern
media@akoyabio.com